Timothy Burgess, M.D., M.P.H.

Timothy H. Burgess, M.D., M.P.H., Captain, Navy

Name: Timothy H. Burgess, M.D., M.P.H., Captain, Navy

USU Department of Primary Appointment: 
Preventive Medicine and Biostatistics
Title: 
Director, IDCRP
Faculty Rank: 
Assistant Professor
Location: 
Uniformed Services University of the Health Sciences, Bethesda, MD

Research Interests:
Infectious diseases, immunology, epidemiology
arboviral disease, respiratory viral disease, vectorborne pathogens, vaccine development

Office Phone: 
(301) 295-1579

Education

M.P.H., Uniformed Services University of the Health Sciences, Bethesda, MD, 1999-2000
Fellowship, Infectious Diseases, National Capitol Consortium, Bethesda, MD, 1997-1999
Residency, Internal Medicine, National Naval Medical Center, Bethesda, MD, 1994-1997
M.D., Indiana University School of Medicine, Indianapolis, IN, 1990-1994
B.S. in Chemistry, U.S. Naval Academy, Annapolis, MD, 1986-1990

Biography

CAPT Burgess currently serves as Director, Infectious Diseases Clinical Research Program (IDCRP). He has served in a variety of research and clinical capacities over 20 years in Navy Medicine. He established the Immunology Section in the Department of Viral and Rickettsial Diseases at the Naval Medical Research Center (NMRC) in 2001, investigating immunopathogenesis of dengue hemorrhagic fever. He then served overseas at Naval Medical Research Unit #2 in Jakarta, Indonesia, where he headed the Viral Diseases Program, conducting studies on dengue hemorrhagic fever and avian influenza and engaging with partners throughout the Asia-Pacific as well as the USG Interagency. He returned to NMRC to head the Viral and Rickettsial Diseases Department where he oversaw vaccine development and diagnostic R&D efforts. Subsequent assignments included Deputy Director of the IDCRP and Chief of the Infectious Diseases clinical service at Walter Reed National Military Medical Center, Bethesda. In January 2016, returned to USUHS as Director of IDCRP. He holds the collateral duty position as Navy Medicine Specialty Leader for Infectious Diseases.

Bibliography

  • Fischer WA Nd, Vetter P, Bausch DG, Burgess T, Davey RT Jr, Fowler R, Hayden FG, Jahrling PB, Kalil AC, Mayers DL, Mehta AK, Uyeki TM, Jacobs M. Ebola virus disease: an update on post-exposure prophylaxis. Lancet Infect Dis. 2017 Nov 15. pii: S1473-3099(17)30677-1. doi: 10.1016/S1473-3099(17)30677-1.
  • Riddle MS, Connor P, Fraser J, Porter CK, Swierczewski B, Hutley EJ, Danboise B, Simons MP, Hulseberg C, Lalani T, Gutierrez RL, Tribble DR; TrEAT TD Study Team. Trial Evaluating Ambulatory Therapy of Travelers' Diarrhea (TrEAT TD) Study: A Randomized Controlled Trial Comparing 3 Single-Dose Antibiotic Regimens With Loperamide. Clin Infect Dis. 2017 Nov 29;65(12):2008-2017. doi: 10.1093/cid/cix693. PubMed PMID: 29029033.
  • Sun P, Crum-Cianflone NF, Defang G, Williams M, Ganesan A, Agan BK, Lalani T, Whitman T, Brandt C, Burgess TH. Evaluation of T and B memory cell responses elicited by the pandemic H1N1 vaccine in HIV-infected and HIV-uninfected individuals. Vaccine. 2017 Oct 27;35(45):6103-6111. doi: 10.1016/j.vaccine.2017.09.059. Epub 2017 Oct 4. PubMed PMID: 28987439.
  • Riddle MS, Martin GJ, Murray CK, Burgess TH, Connor P, Mancuso JD, Schnaubelt ER, Ballard TP, Fraser J, Tribble DR. Management of Acute Diarrheal Illness During Deployment: A Deployment Health Guideline and Expert Panel Report. Mil Med. 2017 Sep;182(S2):34-52. doi: 10.7205/MILMED-D-17-00077. PubMed PMID: 28885922; PubMed Central PMCID: PMC5657341.
  • Beigel JH, Tebas P, Elie-Turenne MC, Bajwa E, Bell TE, Cairns CB, Shoham S, Deville JG, Feucht E, Feinberg J, Luke T, Raviprakash K, Danko J, O'Neil D, Metcalf JA, King K, Burgess TH, Aga E, Lane HC, Hughes MD, Davey RT; IRC002 Study Team. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med. 2017 Jun;5(6):500-511. doi: 10.1016/S2213-2600(17)30174-1. Epub 2017 May 15. PubMed PMID: 28522352.
  • Simmons M, Putnak R, Sun P, Burgess T, Marasco WA. Antibody Prophylaxis Against Dengue Virus 2 Infection in Non-Human Primates. Am J Trop Med Hyg. 2016 Nov 2;95(5):1148-1156. Epub 2016 Sep 19. PubMed PMID: 27645784; PubMed Central PMCID: PMC5094231.
  • PREVAIL II Writing Group; Multi-National PREVAIL II Study Team, Davey RT Jr, Dodd L, Proschan MA, Neaton J, Neuhaus Nordwall J, Koopmeiners JS, Beigel J, Tierney J, Lane HC, Fauci AS, Massaquoi MBF, Sahr F, Malvy D. A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. N Engl J Med. 2016 Oct 13;375(15):1448-1456. PubMed PMID: 27732819; PubMed Central PMCID: PMC5086427.
  • Crum-Cianflone NF, Won S, Lee R, Lalani T, Ganesan A, Burgess T, Agan BK. Vitamin D levels and influenza vaccine immunogenicity among HIV-infected and HIV-uninfected adults. Vaccine. 2016 Sep 22;34(41):5040-5046. doi: 10.1016/j.vaccine.2016.06.019. Epub 2016 Aug 28. PubMed PMID: 27577557.
  • Lalani T, Yun H, Tribble D, Ganesan A, Kunz A, Fairchok M, Schnaubelt E, Fraser J, Mitra I, Kronmann KC, Burgess T, Deiss RG, Riddle MS, Johnson MD. A comparison of compliance rates with anti-vectorial protective measures during travel to regions with dengue or chikungunya activity, and regions endemic for Plasmodium falciparum malaria. J Travel Med. 2016 Jul 4;23(5). doi: 10.1093/jtm/taw043. Print 2016 May. PubMed PMID: 27378367; PubMed Central PMCID: PMC4939934.
  • Koren MA, Arnold JC, Fairchok MP, Lalani T, Danaher PJ, Schofield CM, Rajnik M, Hansen EA, Mor D, Chen WJ, Ridoré M, Burgess TH, Millar EV. Type-specific clinical characteristics of adenovirus-associated influenza-like illness at five US military medical centers, 2009-2014. Influenza Other Respir Viruses. 2016 Sep;10(5):414-20. doi: 10.1111/irv.12392. Epub 2016 May 13. PubMed PMID: 27062998; PubMed Central PMCID: PMC4947946.